NNC0165-1562

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

Metabolism and Nutrition DisorderMetabolism and Nutrition DisordersObesityOverweight or Obesity

Phase 1

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

CompletedNCT02568306

Novo Nordisk A/SMetabolism and Nutrition Disorder, Obesity

Start: 2015-10-05End: 2017-02-07Updated: 2018-07-13

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

CompletedNCT03574584

Novo Nordisk A/SMetabolism and Nutrition Disorders, Overweight or Obesity

Start: 2018-06-18End: 2019-07-27Updated: 2021-07-02